Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab versus placebo and sarilumab in biologic/JAK inhibitor inadequate responder rheumatoid arthritis
2019-000868-18Phase 3Unknown
- Sponsor
- GSK
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of otilimab in rheumatoid arthritis (RA) (4 arms), sponsored by GSK. Primary endpoint: Proportion of participants achieving ACR20. Status: unknown.
02
Drugs
otilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-000868-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000868-18.